This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Targeting Vascular Inflammation to Reduce Cardiovascular Risk

Targeting Vascular Inflammation to Reduce Cardiovascular Risk


Interactive Monograph

Time to Complete

1 hour


January 26, 2018


January 26, 2019
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Integrity Continuing Education, Inc.

Commercial Supporter

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Program Description

Cardiovascular (CV) disease, specifically coronary heart disease, represents a significant healthcare burden. An improved understanding of the atherothrombotic processes has led to the identification of biomarkers associated with increased CV risk, such as low-density lipoprotein cholesterol and high-sensitivity C-reactive protein, a biomarker for inflammation. In order to address the need to reduce CV events among patients at an increased vascular risk due to elevated levels of C-reactive protein, trials are being conducted to investigate the effect of targeting inflammation to reduce CV risk. Improving knowledge of the role of vascular inflammation (VI) in mediating atherothrombosis will provide the foundation to assess the most recent clinical evidence on the correlation between inflammation and atherothrombosis and the rationale to target inflammatory pathways.

Intended Audience

This educational initiative has been designed for cardiologists, internal medicine physicians, and other healthcare providers involved in the care of patients with VI.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Discuss the inflammatory processes that contribute to atherothrombosis
  • Recognize the need to target inflammation for the prevention of atherothrombosis
  • Evaluate data from clinical trials targeting VI to reduce recurrence of CV events
  • Identify patients with heart disease that will benefit from anti-inflammatory therapy

Conflict Of Interest Disclosure Policy

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity under the Faculty heading below.


Paul M. Ridker, MD, MPH, FACC
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Eugene Braunwald Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Ridker discloses the following:
Consulting fees: AstraZeneca, Quintiles, Sanofi, TEVA
Contracted research: American Heart Association, Amgen, AstraZeneca, Donald W. Reynolds Foundation, Doris Duke Charitable Foundation, James and Polly Annenberg La Vea Charitable Trusts, Kowa Pharmaceuticals, Leducq Foundation, National Cancer Institute, National Heart, Lung, and Blood Institute, Novartis Pharmaceuticals Corporation, Pfizer
Patent holder: Co-inventor on patents held by Brigham and Women’s Hospital and licensed to AstraZeneca and Siemens

Brendan M. Everett, MD, MPH
Director, General Cardiology Inpatient Service
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Dr. Everett discloses the following:
Consulting fees: Novartis Pharmaceuticals Corporation, Roche Diagnostics
Contracted research: Kowa Pharmaceuticals, National Heart, Lung, and Blood Institute, Novartis Pharmaceuticals Corporation

Accredited Provider Disclosure

Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation Statement

Integrity Continuing Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. and Novartis Pharmaceuticals Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.


There are no fees for participating and receiving CME credit for this activity. During the period of January 26, 2018 through January 26, 2019, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher.

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or

If you have any questions relating to your certificate or other issues with this activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue